Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
michael.pavlides@cardiov.ox.ac.uk

Research groups

Pavlides Group: Quantitative MR and liver disease

Michael Pavlides

Head of liver imaging at OCMR

Principal Investigator
Honorary consultant at Oxford University Hospitals NHS Trust

Recent publications

Editorial: Prediction of Survival in Hepatocellular Cancer—Rise and Fall of the Machines

Pavlides M., (2026), Alimentary Pharmacology & Therapeutics

Lowering the bar? Noninvasive tests for identifying significant fibrosis in metabolic dysfunction-associated steatotic liver disease.

Pavlides M. and Appiah E., (2026), Pol Arch Intern Med, 136

Quantitative magnetic resonance cholangiopancreatography metrics improve prognostication in primary sclerosing cholangitis.

Middelburg TE. et al, (2026), JHEP Rep

The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus.

Cobbold JF. et al, (2026), Lancet Gastroenterol Hepatol

Periductal iron-corrected T1 is a predictor of adverse outcomes in large-duct primary sclerosing cholangitis.

Selvaraj EA. et al, (2026), BMC Med Imaging, 26

More publications